Recent Posts
Roche’s GA101 (obinutuzumab): Engineering an antibody to beat Rituxan
The following is a guest post from Sally Church (known to many in the...
Biotech, Pharma, & VCs Offer Rare Disease Patient Groups Some Advice
Today’s issue examines the surge of interest in rare disease drugs, which...
Liveblogging First-Time Disclosures of Drug Structures from #ACSNOLA
Bookmark this page now, folks. On Wednesday, April 10, I will be here,...
New Targets in Advanced Prostate Cancer
The following is a guest post from Sally Church (known to many in the...
New developments in Advanced Pancreatic Cancer from ASCO GI 2013 – Part 2
The following is a guest post from Sally Church (known to many in the...
New Developments in Advanced Pancreatic Cancer from ASCO GI 2013 – Part 1
The following is a guest post from Sally Church (known to many in the...
#FoodChem Carnival: A bit o’ science on your Thanksgiving tippling
In my family, the first thing that happens when you walk in the door to my...
#ChemCoach Carnival: From Big Pharma to Non-Profit
We're almost at the end of National Chemistry week, folks, and the Haystack...
Cantley Talks Pfizer CTI Collaboration
As drug companies forge closer ties with academic researchers, the value of...
After Nutley Closure, Roche Picks NYC For East Coast R&D Site
Just months after announcing it would close its storied Nutley, N.J.,...
Recent Comments